首页 › 基金 › BENDER ROBERT & ASSOCIATES › BCRX
BENDER ROBERT & ASSOCIATES 对 BCRX 的持仓历史
BIOCRYST PHARMACEUTICALS INC · 医疗保健
BENDER ROBERT & ASSOCIATES 在 Q3 2026 的 13F 申报中披露持有 BCRX(BIOCRYST PHARMACEUTICALS INC)23,710 股,市值约 US$198K,约占其申报组合的 0.04%,在其申报持仓中市值排名第 45 位。 BENDER ROBERT & ASSOCIATES 最近 13 个申报季度中有 7 个季度披露了 BCRX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
BENDER ROBERT & ASSOCIATES 对 BCRX 的持仓演变
BENDER ROBERT & ASSOCIATES 于 Q3 2023 首次披露 BCRX 持仓:56,600 股(约 US$401K)。 在 7 次申报中,BENDER ROBERT & ASSOCIATES 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 23,710 股、市值约 US$198K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 56.60K | $400.73K | 新进 |
| Q4 2023 | 56.60K | $339.03K | 持有 |
| Q4 2024 | 23.71K | $178.30K | 新进 |
| Q2 2025 | 23.71K | $212.44K | 新进 |
| Q3 2025 | 23.71K | $179.96K | 持有 |
| Q1 2026 | 23.71K | $225.72K | 新进 |
| Q3 2026 | 23.71K | $197.50K | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BCRX 与 13F 数据
BCRX(BIOCRYST PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 46 只申报持有 BCRX,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BCRX 的基金
- RA CAPITAL MANAGEMENT, L.P. 15.83M 股 · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M 股 · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M 股 · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M 股 · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M 股 · $83.00M · Q2 2026
- Jones Hill Capital LP 7.08M 股 · $59.00M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.01M 股 · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M 股 · $25.23M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M 股 · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M 股 · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M 股 · $18.66M · Q2 2026
- Parkman Healthcare Partners LLC 1.62M 股 · $16.24M · Q2 2026
更多关于 BENDER ROBERT & ASSOCIATES
常见问题
How long has BENDER ROBERT & ASSOCIATES held BCRX?
BENDER ROBERT & ASSOCIATES has disclosed BCRX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is BENDER ROBERT & ASSOCIATES's current position in BCRX?
As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 23.71K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $197.50K, representing 0.04% of its reported portfolio and ranking #45.
Has BENDER ROBERT & ASSOCIATES been buying or selling BCRX?
In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES newly opened its position in BCRX.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.